Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Congestive Heart Failure (PREVENT-CHF):A Phase IIB Randomized Placebo-Controlled Trial

In order for our site to display correctly you will need a newer version of your web browser.

Currently we test and support the following browsers:

FireFox version 3.0 and above (Windows and Mac)
Safari version 5.0 and above (Windows and Mac)
Internet Explorer version 7.0 and above (Windows)

Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.

Research

Supportive Studies

Protocol

PREVENT: Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Congestive Heart Failure (PREVENT-CHF):A Phase IIB Randomized Placebo-Controlled Trial

Diseases

Phase I Studies : congestive heart failure

Description

Anthracyclines are chemotherapy drugs commonly used in the treatment of many childhood cancers. High doses of anthracyclines are known to increase the risk of heart muscle weakness (cardiomyopathy) and congestive heart failure. This study is designed to measure what effect taking low-dose Carvedilol for two years might have on preventing the heart muscle changes that can lead to cardiomyopathy and congestive heart failure. Survivors of childhood cancers who received 300 mg/m2 or more of anthracyclines will be randomly (like tossing a coin) assigned to take a low dose of Carvedilol or an identical looking pill which contains no medicine (placebo).

Objectives

To learn if taking a low dose of Carvedilol for two years prevents the heart muscle changes that can lead to cardiomyopathy and congestive heart failure in survivors of childhood cancer treated with high doses of anthracycline chemotherapy.
To learn how well low-dose Carvedilol is tolerated in survivors of childhood cancer treated with high doses of anthracycline chemotherapy.
To learn about the side effects of Carvedilol in survivors who were treated with high doses of anthracycline chemotherapy.

Eligibility

Participant is > 16 years of age.
Participant had cancer diagnosis < 21 years of age.
Participant has lifetime cumulative anthracycline dose >300 mg/m2.
Participant is > 2 years since completion of treatment for cancer.
Participant is not receiving treatment for cardiomyopathy or congestive heart failure.
Participant’s heart rate is > 60 beats per minute.

For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).

Contact

Melissa M. Hudson MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-888-226-4343 or 901-595-4055
FAX: 901-595-4011

Referring or consulting physicians only: protocolinfo@stjude.org

For all other inquiries about St. Jude Children's Research Hospital studies: info@stjude.org

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Print Email This Article